The pathologist and toxicologist in pharmaceutical product discovery

Toxicologic Pathology

Volumn 27, Issue 1, 1999, Pages 104-106

  Alden, Carl L ^a   Sagartz, John E ^a   Smith, Peter F ^b   Wilson, Alan G ^a   Bunch, Roderick T ^b   Morris, Dale L ^a  

^a MONSANTO COMPANY   (United States)

^b Monsanto Life Sciences   (United States)

Author keywords

Efficacy models; Pathologist; Pharmaceutical discovery; Toxicologist

Indexed keywords

CONFERENCE PAPER; CYTOTOXICITY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SCREENING; PRIORITY JOURNAL; RISK ASSESSMENT; TOXICITY TESTING;

ANIMALIA;

EID: 0032979905     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1177/019262339902700119     Document Type: Conference Paper

References (4)

1. Balwierz P and Bunch T (1998). An in situ micronucleus assay: Implications for drug discovery. Environ. Mol. Mutagen 31(suppl. 29): 3.
2. Davila J and Morris D (1999). Analysis of cytochrome P450 and phase II conjugating enzyme expression in adult male rat hepatocytes. In Vitro Cell. Dev. Biol. 35: 1-11 (in press).
3. International Conference on Harmonisation (March 1995). Fed. Register 60(40): 11274-11275.
4. Phillips J, Gibson W, Hard G, and Alden C (1990). Survey of QSAR and in vitro approaches for developing non-animal methods to supersede the in vivo LD50 test. Food Chem. Toxicol. 28: 375-394.